ATE263237T1 - Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung - Google Patents

Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung

Info

Publication number
ATE263237T1
ATE263237T1 AT99201866T AT99201866T ATE263237T1 AT E263237 T1 ATE263237 T1 AT E263237T1 AT 99201866 T AT99201866 T AT 99201866T AT 99201866 T AT99201866 T AT 99201866T AT E263237 T1 ATE263237 T1 AT E263237T1
Authority
AT
Austria
Prior art keywords
libraries
efficient method
nucleic acids
gene functions
sample nucleic
Prior art date
Application number
AT99201866T
Other languages
English (en)
Inventor
Govert Schouten
Ronald Vogels
Abraham Bout
Es Helmuth Van
Original Assignee
Galapagos Genomics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics Nv filed Critical Galapagos Genomics Nv
Application granted granted Critical
Publication of ATE263237T1 publication Critical patent/ATE263237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
AT99201866T 1998-06-12 1999-06-11 Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung ATE263237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/097,239 US6413776B1 (en) 1998-06-12 1998-06-12 High throughput screening of gene function using adenoviral libraries for functional genomics applications

Publications (1)

Publication Number Publication Date
ATE263237T1 true ATE263237T1 (de) 2004-04-15

Family

ID=22262382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99201866T ATE263237T1 (de) 1998-06-12 1999-06-11 Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung

Country Status (10)

Country Link
US (3) US6413776B1 (de)
EP (1) EP1022335B1 (de)
JP (1) JP3672494B2 (de)
AT (1) ATE263237T1 (de)
AU (1) AU756605B2 (de)
CA (1) CA2301403C (de)
DE (1) DE69916005T2 (de)
MX (1) MXPA00012401A (de)
NZ (1) NZ508995A (de)
WO (1) WO1999064582A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766891A (en) * 1994-12-19 1998-06-16 Sloan-Kettering Institute For Cancer Research Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
DE69633565T3 (de) * 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
NZ520579A (en) * 1997-10-24 2004-08-27 Invitrogen Corp Recombinational cloning using nucleic acids having recombination sites and methods for synthesizing double stranded nucleic acids
WO1999051620A1 (en) * 1998-04-03 1999-10-14 Invitrogen Corporation Libraries of expressible gene sequences
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2345356C (en) 1998-10-06 2012-10-02 Mark Aaron Emalfarb Transformation system in the field of filamentous fungal hosts
WO2000044894A1 (de) * 1999-01-29 2000-08-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur isolation von apoptose-induzierenden dna-sequenzen und detektionssystem
US6642052B2 (en) * 1999-02-25 2003-11-04 National Research Council Of Canada Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU2368201A (en) * 1999-12-23 2001-07-09 Xantos Biomedicine Ag Screening method for nucleic acids
AU2001234980A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Methods of preparing and using a viral vector library
EP1261724A4 (de) 2000-02-25 2004-08-18 Invitrogen Corp Topoisomerase linker-vermittelte amplifizierungsverfahren
US7216113B1 (en) * 2000-03-24 2007-05-08 Symyx Technologies, Inc. Remote Execution of Materials Library Designs
KR20020026456A (ko) 2000-04-13 2002-04-10 에말파브 마크 아론 사상균에서 발현된 ｄｎａ 라이브러리의 고산출량 스크리닝
US20030104494A1 (en) * 2001-10-26 2003-06-05 Ilya Ravkin Assay systems with adjustable fluid communication
EP1276888A2 (de) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirale vektoren ohne knob-domäne im fiber protein, und verwendungen davon
EP1313851B1 (de) * 2000-08-21 2006-01-04 Invitrogen Corporation Methoden und reagenzien für molekulares klonieren
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
AU2002248173B2 (en) * 2000-12-08 2007-04-26 Invitrogen Corporation Compositions and methods for rapidly generating recombinant nucleic acid molecules
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP1227157A1 (de) * 2001-01-19 2002-07-31 Galapagos Genomics B.V. Swap/Gegenselektion: eine schnelles Klonierungsverfahren
KR20030090626A (ko) * 2001-01-25 2003-11-28 비륵시스 코포레이션 유전자 기능을 동정하기 위한 방법 및 조성물
WO2002070744A2 (en) * 2001-03-07 2002-09-12 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US20040132008A1 (en) * 2002-04-30 2004-07-08 Doranz Benjamin J Elucidation of gene function
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
US20030059811A1 (en) * 2001-06-14 2003-03-27 Hakim Djaballah Methods of screening for ligands of target molecules
EP1273667A1 (de) * 2001-07-04 2003-01-08 Galapagos Genomics N.V. Hochdurchsatzidentifizierung von Angiogenese Modulatoren
US7691995B2 (en) 2001-07-12 2010-04-06 University Of Massachusetts In vivo production of small interfering RNAS that mediate gene silencing
EP1417306A2 (de) * 2001-08-10 2004-05-12 Xantos Biomedicine AG Hochdurchsatz dna-isolierung und -transfektion zur analyse der funktion von genen bzw. genprodukten
JP2005503792A (ja) * 2001-08-22 2005-02-10 ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US20080187949A1 (en) * 2001-10-26 2008-08-07 Millipore Corporation Multiplexed assays of cell migration
US7381375B2 (en) 2001-10-26 2008-06-03 Millipore Corporation Assay systems with adjustable fluid communication
JP2005514959A (ja) * 2002-01-24 2005-05-26 エコピア バイオサイエンシーズ インク 微生物から二次代謝産物を同定するための方法、システム及び情報リポジトリ
WO2003104455A1 (en) * 2002-06-07 2003-12-18 Sophion Bioscience A/S Screening methods
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
ES2343518T3 (es) 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
JP4287633B2 (ja) * 2002-09-18 2009-07-01 独立行政法人科学技術振興機構 オルガネラ局在タンパク質の解析方法と解析材料
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20080207465A1 (en) * 2002-10-28 2008-08-28 Millipore Corporation Assay systems with adjustable fluid communication
CA2506894A1 (en) * 2002-11-21 2004-06-03 Genomidea Inc. Method of isolating nucleic acid having desired functional property and kit therefor
EP1573012B1 (de) 2002-12-17 2011-11-30 Crucell Holland B.V. Rekombinanter virus-basierter malaria impfstoff
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
US20050059083A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company High throughput method to identify ligands for cell attachment
US20050060100A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company Computer software and algorithms for systems biologically linked to cellular phenotype
DE602004027538D1 (de) * 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
WO2005063983A1 (en) * 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
MXPA06011738A (es) * 2004-04-15 2007-01-25 Allied Biotech Inc Metodos y aparato para la deteccion de infeccion viral.
ATE483981T1 (de) 2004-04-20 2010-10-15 Galapagos Nv Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
GB0410105D0 (en) * 2004-05-06 2004-06-09 Amersham Biosciences Uk Ltd Method for characterising compounds
CA2569511A1 (en) 2004-06-14 2005-12-22 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
EP2360474B1 (de) 2004-06-21 2013-07-24 Galapagos N.V. Verfahren und Mittel zur Behandlung von Osteoarthritis
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US8680252B2 (en) 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
JP2010538244A (ja) 2007-06-20 2010-12-09 ガラパゴス・ナムローゼ・フェンノートシャップ 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
CA2736661A1 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
CL2009001064A1 (es) 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
AU2009290848A1 (en) 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
US20170247762A1 (en) 2014-10-27 2017-08-31 The Board Institute Inc. Compositions, methods and use of synthetic lethal screening
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
EP3336169A1 (de) * 2016-12-15 2018-06-20 Institut Polytechnique de Grenoble Robotisches verfahren zum beschichten einer multiwellplatte durch einen mehrschichtigen polyelektrolytfilm
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
WO2019136169A1 (en) * 2018-01-04 2019-07-11 Arizona Board Of Regents On Behalf Of Arizona State University Versatile amplicon single-cell droplet sequencing-based shotgun screening platform to accelerate functional genomics
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11608491B2 (en) 2019-02-22 2023-03-21 Life Technologies Corporation Suspension system for adeno associated virus production
US12049638B2 (en) 2019-07-23 2024-07-30 Janssen Biotech, Inc. Synthetic genetic elements for biomanufacture
US20230203477A1 (en) 2020-05-26 2023-06-29 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
MX2023007003A (es) 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
WO1995002697A1 (fr) 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5401744A (en) 1993-10-04 1995-03-28 Bristol-Myers Squibb Company Useful hemi-hydrate form of a cerebral function enhancing agent
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
EP0784690B1 (de) 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
EP0707071B1 (de) 1994-08-16 2003-07-30 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
NZ330553A (en) * 1996-01-05 2001-04-27 Genetic Therapy Inc Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated
US6455247B1 (en) 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
AU2100499A (en) * 1997-12-19 1999-07-12 Genetrace Systems, Inc. Non-bacterial cloning in delivery and expression of nucleic acids
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Also Published As

Publication number Publication date
US20030027170A1 (en) 2003-02-06
DE69916005D1 (de) 2004-05-06
JP2002526031A (ja) 2002-08-20
WO1999064582A3 (en) 2000-04-06
EP1022335A1 (de) 2000-07-26
US7029848B2 (en) 2006-04-18
US6340595B1 (en) 2002-01-22
AU756605B2 (en) 2003-01-16
CA2301403C (en) 2009-01-06
JP3672494B2 (ja) 2005-07-20
EP1022335B1 (de) 2004-03-31
CA2301403A1 (en) 1999-12-16
WO1999064582A2 (en) 1999-12-16
DE69916005T2 (de) 2004-09-09
AU4294799A (en) 1999-12-30
NZ508995A (en) 2003-12-19
MXPA00012401A (es) 2003-07-14
US6413776B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
DE69916005D1 (de) Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
ATE118818T1 (de) Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.
ATE118549T1 (de) Verfahren zur synthese von ribonukleinsäure (rns).
ATE343586T1 (de) Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung
ATE141956T1 (de) Verfahren zur vervielfältigung von nukleinsäuresequenzen
DE60127162D1 (de) Massives Parallelverfahren zur Dekodierung von DNA und RNA
ATE545710T1 (de) Verfahren zur vervielfältigung von nukleinsäuren
DE69738254D1 (de) Methode zur bereitstellung von dna sequenzen
DE69636835D1 (de) Verfahren zur verwendung der nukleotid-integrase zur spaltung von dna und zum einbau von nukleinsäuren
AU2003291610A1 (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage)
EP1480155A3 (de) Informationsverarbeitungsanlage, Informationsverarbeitungsverfahren, Speichermedium und Programm
WO2000022171A3 (en) Systems and methods for sequencing by hybridization
DE69940890D1 (de) Ein verfahren zur analyse von polynukleotiden
ATE278808T1 (de) Verfahren zur charakterisierung von nukleinsäurefragmenten
ATE211180T1 (de) Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit
ATE264865T1 (de) Verfahren zum nachweis von biologischen materialen mit boviner herkunft, und oligonukleotiden die es gebraucht
ATE396281T1 (de) Quantifizierungsverfahren für genetische modifikationen unter verwendung von standardmolekülen
DE59410068D1 (de) Verfahren zur spezifischen Klonierung von Nukleinsäuren
ATE144557T1 (de) Nucleinsäure-proben und verfahren zum nachweis von giardia lamblia
DE50014875D1 (de) Verfahren zum herstellen eines rekombinanten proteins
ATE317123T1 (de) Reaktiver träger zur bestimmung von dna fragmenten
PT778347E (pt) Proteina ligante a atp e acidos nucleicos com propriedade de helicase e de atpase
WO2000021984A3 (en) Nucleic acids encoding human cide-b protein and polymorphic markers thereof
WO2001040510A3 (de) Dynamische sequenzierung durch hybridisierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
EEFA Change of the company name